Skip to main content
David Knopman, MD, Neurology, Rochester, MN, Mayo Clinic Hospital - Rochester

DavidSKnopmanMD

Neurology Rochester, MN

Neurodegenerative, Dementia & Geriatrics

Professor, Neurology, Mayo Medical School

Dr. Knopman is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Knopman's full profile

Already have an account?

Summary

  • Dr. David Knopman is a neurologist at the Mayo Clinic, Rochester. He received his medical degree from University of Minnesota Medical School and has been in practice 42 years. He specializes in neurodegenerative and dementia & geriatrics.

Education & Training

  • University of Minnesota
    University of MinnesotaResidency, Neurology, 1976 - 1979
  • Hennepin Healthcare
    Hennepin HealthcareInternship, Transitional Year, 1975 - 1976
  • University of Minnesota Medical School
    University of Minnesota Medical SchoolClass of 1975
  • Dartmouth College
    Dartmouth CollegeA.B., Biology, 1972

Certifications & Licensure

  • MN State Medical License
    MN State Medical License 1978 - 2024
  • American Board of Psychiatry and Neurology Neurology

Awards, Honors, & Recognition

  • Phi Beta Kappa Honor Society 1972
  • Whos Who in Medicine and Healthcare Marquis Whos Who

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Association of Initial Β-amyloid Levels with Subsequent Flortaucipir Positron Emission Tomography Changes in Persons Without Cognitive Impairment  
    David S Knopman, Bradley F Boeve, Ronald C Petersen, Clifford R Jack, JAMA Neurology
  • Rates of Brain Atrophy Across Disease Stages in Familial Frontotemporal Dementia Associated with MAPT, GRN, and C9orf72 Pathogenic Variants  
    Nupur Ghoshal, Neill R Graff-Radford, David S Knopman, Zbigniew K Wszolek, Joel H Kramer, Bradley F Boeve, Howard J Rosen, JAMA Network Open
  • Association Between Functional Performance and Alzheimer's Disease Biomarkers in Individuals Without Dementia  
    Mary M Machulda, Ronald C Petersen, David S Knopman, Yonas E Geda, Val J Lowe, Journal of the American Geriatrics Society
  • Join now to see all

Books/Book Chapters

  • Join now to see all

Abstracts/Posters

  • Tdp-43 influences cognition, memory loss and hippocampal atrophy in Alzheimer's disease.
    Josephs K, Whitwell J, Weigand S, Murray M, Tosakulwong N, Liesinger A, Petrucelli L, Knopman D, Boeve B, Ivnik R, Smith G, Jack C, Parisi J, Petersen R, Dickson D, J Neuropathol Exp Neurol, 6/1/2014
  • Antemortem characterization of a kindred carrying the non-coding GGGGCC hexanucleotide repeat expansion in C9ORF72.
    Adeli A, Boeve B, DeJesus-Hernandez M, Baker M, Rutherford N, Knopman D, Ivnik R, Fields J, Petersen R, Rademakers R, Neurology, 4/1/2012
  • Characterization of the neuropsychiatric features associated with mutations in C9ORF72'MAPT and PGRN.
    Adeli A, Geda Y, Boeve B, Graff-Radford N, DeJesus-Hernandez M, Knopman D, Josephs K, Pedraza O, Rush B, Fields J, Rutherford N, Baker M, Smith G, Ivnik R, Pankratz V,..., Neurology, 4/1/2012
  • Join now to see all

Lectures

  • Alzheimers Disease 
    Curitiba, Brazil - 4/1/2004
  • Symptoms of Dementia 
    University of Colorado - 3/1/2004
  • 7th International Conference on Alzheimer's Disease 
    7/1/2000
  • Join now to see all

Press Mentions

  • Alzheimer’s Drugs Are Arriving, but They Won’t Be Risk Free
    Alzheimer’s Drugs Are Arriving, but They Won’t Be Risk FreeMay 23rd, 2023
  • And Then There Were Three: Donanemab Phase 3 Trial Positive
    And Then There Were Three: Donanemab Phase 3 Trial PositiveMay 4th, 2023
  • Does Brain Power Shield from Obesity? Probably Not
    Does Brain Power Shield from Obesity? Probably NotApril 13th, 2023
  • Join now to see all

Grant Support

  • Validating The New Criteria For Preclinical Alzheimer'S DiseaseNational Institute On Aging2012
  • Frontotemporal Degeneration: A Basis For Clinical TrialsNational Institute On Aging2004–2006
  • Frontotemporal Degeneration: A Basis For Clinical TrialsNational Institute On Aging2003
  • Epidemiology Of Alzheimer Disease In A Total PopulationNational Institute On Aging1992–1994
  • Scientific Evaluation And PlanningNational Institute Of Mental Health1991–1994

Hospital Affiliations